TY  - GEN
AU  - O'Boyle,Niamh M
AU  - Meegan,Mary J
TI  - Anticancer Drugs
SN  - books978-3-03921-587-4
PY  - 2019///
PB  - MDPI - Multidisciplinary Digital Publishing Institute
KW  - graphene oxide
KW  - indole
KW  - androgens
KW  - cyclooxygenase-2
KW  - cyclooxygenase-1
KW  - heteropolysaccharide
KW  - drug conjugation
KW  - drug delivery
KW  - ellipticine
KW  - chemical linker
KW  - oesophageal cancer
KW  - antiproliferative activity
KW  - topoisomerase II
KW  - ?-lactam
KW  - DSD
KW  - antibody
KW  - topoisomerase inhibitors
KW  - magnetic targeting
KW  - cisplatin resistance
KW  - steroidogenesis
KW  - [18F]FDG PET/CT
KW  - heterocyclic chemistry
KW  - dehydroepiandrosterone
KW  - antimitotic
KW  - 3-vinylazetidin-2-ones
KW  - glioblastoma
KW  - and cancer therapy
KW  - intestinal mucositis
KW  - Combretastatin A-4
KW  - metabolism
KW  - anti-cancer drugs
KW  - maghemite
KW  - COX-1 inhibitor
KW  - anticancer
KW  - CYP17A1
KW  - conjugate and hybrid drugs
KW  - inflammation
KW  - snticancer drugs
KW  - P450c17
KW  - tumorigenesis
KW  - cisplatin
KW  - biomarker profiling
KW  - cancer drug design
KW  - tubulin
KW  - cytochrome P450
KW  - 5-fluorouracil
KW  - prostate cancer
KW  - abiraterone
KW  - NCI screen
KW  - radiation
KW  - cancer immunotherapy
KW  - microtubule targeted drugs
KW  - cancer
KW  - treatment resistance
N1  - Open Access
N2  - The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myeloid leukaemia with imatinib, and the success of biological drugs. The transition from cytotoxic chemotherapy to targeted cancer drug discovery and development has resulted in an increasing selection of tools available to oncologists. In this Special Issue of Pharmaceuticals, we highlight the opportunities and challenges in the discovery and design of innovative cancer therapies, novel small-molecule cancer drugs and antibody-drug conjugates, with articles covering a variety of anticancer therapies and potential relevant disease states and applications. Significant efforts are being made to develop and improve cancer treatments and to translate basic research findings into clinical use, resulting in improvements in survival rates and quality of life for cancer patients. We demonstrate the possibilities and scope for future research in these areas and also highlight the challenges faced by scientists in the area of anticancer drug development leading to improved targeted treatments and better survival rates for cancer patients
UR  - https://mdpi.com/books/pdfview/book/1662
UR  - https://directory.doabooks.org/handle/20.500.12854/40955
ER  -